Filing summary
Important identity discrepancy: The request identifies Opus Genetics, Inc., but the supplied 10-Q is for Rexahn Pharmaceuticals, Inc. The summary below reflects the filing text, not Opus Genetics.
Business context and reporting period
This is Rexahn’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2017. Rexahn describes itself as a clinical-stage cancer therapeutics company with no product sales. Its three clinical-stage candidates were RX-3117, Supinoxin (RX-5902), and Archexin; it also had preclinical programs.
Financial performance and liquidity
| Metric | Q3 2017 | Nine months 2017 | Comparable 2016 period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Operating expenses | $4.22 million | $12.46 million | $3.72 million; $12.49 million |
| Net loss | $1.04 million | $21.70 million | $2.87 million; $8.78 million |
| Basic and diluted loss per share | $0.04 | $0.83 | $0.13; $0.42 |
| Cash used in operating activities | Not presented quarterly | $11.72 million | $11.73 million for nine months |
At September 30, 2017, cash and cash equivalents were $8.23 million and marketable securities were $14.98 million, totaling $23.20 million in cash and short-term investments. Current assets were $24.48 million and current liabilities were $9.47 million. Total liabilities included $6.68 million of warrant liabilities; the filing does not show conventional borrowings as a material liability. The company reported stockholders’ equity of $15.12 million.
Gross margin is not meaningful because the company reported no revenue. Nine-month research and development expense was $7.45 million, down 6.9% year over year; general and administrative expense was $5.00 million, up 11.4%. Q3 R&D rose 15.1% to $2.64 million and G&A rose 10.9% to $1.57 million.
Material changes and unusual items
- Nine-month net loss worsened substantially from 2016, primarily because the company recorded a $9.05 million unrealized loss on warrant fair value, versus a $3.94 million unrealized gain in 2016. Q3 included a $3.12 million warrant-related unrealized gain, versus a $0.97 million gain in Q3 2016. These are non-cash valuation changes.
- R&D spending shifted by program: nine-month RX-3117 costs increased to $3.13 million, while Supinoxin and Archexin costs decreased. Management attributed much of the year-over-year R&D variation to the timing of drug manufacturing campaigns and clinical activity.
- Financing provided $14.67 million in cash during the first nine months, including $9.24 million in net proceeds from the June 2017 offering and $5.35 million from warrant exercises. The company issued 3.03 million shares and warrants in the June offering.
- After quarter-end, an October 17 offering generated $8.00 million gross proceeds through a further share-and-warrant issuance. The filing reports 31,725,114 common shares outstanding as of November 3, 2017.
- The company effected a one-for-ten reverse stock split on May 5, 2017; share and per-share figures were retroactively adjusted.
Outlook, risks, and contingencies
Management expected cash, cash equivalents, and marketable securities to cover cash needs for current activities for at least 12 months from issuance of the financial statements. It also stated that additional capital will be needed to continue drug development and that unavailable or unfavorable financing could require reduced R&D activity.
Management expected R&D expense to increase in the remainder of 2017 versus Q3, citing continued trial enrollment and new manufacturing campaigns. It anticipated additional RX-3117 spending, including a planned combination trial with Abraxane; higher Supinoxin spending for trial enrollment and manufacturing; Archexin expense broadly flat; and preclinical spending broadly flat.
Key risks include clinical-trial delays or failure, regulatory uncertainty, dependence on third-party research organizations and manufacturers, intellectual-property risks, lack of profitability, and the need for additional capital. The company reported no material changes to the risk factors in its 2016 Form 10-K. Vendor agreements had estimated remaining costs of approximately $10.75 million at September 30, 2017 and could generally be terminated with required notice. Certain license milestone payments are contingent on future development or marketing approvals and had not been triggered. No off-balance-sheet arrangements were reported.
Important facts for investors to verify
- Confirm whether the intended filing is Rexahn’s 2017 Q3 10-Q or a filing for Opus Genetics; the supplied document names Rexahn throughout.
- Review the warrant-liability valuation assumptions and the resulting non-cash gains and losses, which materially affected reported net loss.
- Assess the cash runway against ongoing clinical, manufacturing, and vendor commitments, and account for the October 2017 financing and its dilution.
- Check subsequent clinical-trial progress, enrollment, manufacturing needs, and any updates to management’s stated spending outlook.
- Review the full 10-K risk disclosures and contingent license obligations; this summary does not establish clinical efficacy or future financing availability.